Loading
Nerve damage from taxanes and platinum is common, often permanent and has no approved preventive. Test the most promising candidates head to head in one programme.
Chemotherapy-induced peripheral neuropathy affects a large share of patients treated with taxanes, platinum or bortezomib and drives dose reduction. SARM1, an executioner of axon degeneration, is validated genetically in mouse models and inhibitors are in early clinical development for other neuropathies; HDAC6 inhibitors and cryotherapy or compression of hands and feet have supportive data. The proposal is a multi-arm platform trial in adjuvant breast and colorectal cancer comparing candidate preventives against placebo with a patient-reported neuropathy endpoint (EORTC CIPN20) and quantitative sensory testing.
Shares EX-CIPN: virtual exercise-based rehabilitation for persistent chemotherapy nerve damage, Nerve damage from chemotherapy: what recovers, and what helps, Paclitaxel / nab-paclitaxel, Toxicity and quality of life are undervalued.
Shares Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials, Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs, Toxicity and quality of life are undervalued, Platinum agents.
Shares Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs, Paclitaxel / nab-paclitaxel, Toxicity and quality of life are undervalued, HR-positive / HER2-negative breast cancer.
Shares Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs, Paclitaxel / nab-paclitaxel, Platinum agents, Cytotoxic chemotherapy.
Shares Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs, Toxicity and quality of life are undervalued, Cytotoxic chemotherapy, Colorectal cancer.
Shares Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials, Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards, Toxicity and quality of life are undervalued.
Shares Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials, Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards, Toxicity and quality of life are undervalued.
Shares Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials, Toxicity and quality of life are undervalued.